Unlock instant, AI-driven research and patent intelligence for your innovation.

Crystalline forms of [1,2,4]triazolo[1,5-a]pyridine derivatives with antitumor activity

A technology of anti-tumor drugs and crystal forms, which is applied in the field of crystal forms of [1,2,4]triazolo[1,5-a]pyridine derivatives, which can solve the problems of low bioavailability, large toxic and side effects, exclusive Issues such as weak sex

Active Publication Date: 2018-06-26
WEST CHINA HOSPITAL SICHUAN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, although there are many drugs for the treatment of lung cancer on the market, they all have various defects, such as low bioavailability, low specificity, and large toxic and side effects.
These defects are often caused by the structural characteristics of the compound itself and its target, and it is difficult to overcome it in further research and development.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystalline forms of [1,2,4]triazolo[1,5-a]pyridine derivatives with antitumor activity
  • Crystalline forms of [1,2,4]triazolo[1,5-a]pyridine derivatives with antitumor activity
  • Crystalline forms of [1,2,4]triazolo[1,5-a]pyridine derivatives with antitumor activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 2-amino-5-[4-(4-morpholinomethyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridine (compound 1) crystal form A preparation of

[0034]

[0035] Add 2ml of water and 10ml of 1,4-dioxane into a 25ml round bottom flask, stir and mix well, then add 2.85g (9.40mmol) of 4-(4-morpholinomethyl) phenylboronic acid pinacid, K 2 CO 3 1.30g (0.63mmol), PdCl 2 dppf 0.34g (0.46mmol), 5-bromo-[1,2,4]triazol[1,5-a]pyridin-2-amine 2g (9.29mmol), stirred at room temperature for 10 minutes, the reaction solution was yellow; The reaction bottle was transferred to an oil bath for reflux at 90° C. After 1 hour, the reaction solution turned from yellow to black, and the reaction was continued for 3-5 hours until the reaction was detected by TLC (developing agent: 5% CH 3 OH / CH 2 Cl 2 ); then want to add 10ml water to the flask to terminate the reaction, transfer to a 50ml beaker, CH 2 Cl 2 Extract (3×50ml), combine the organic phases, add 1g of anhydrous magnesium sulfate, filter, ...

Embodiment 2

[0045] Example 2 2-iodo-5-[4-(4-morpholinomethyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridine (compound 2) crystal form B preparation of

[0046]

[0047] Add 100mg (0.32 mmol) and 8 mL of acetonitrile, after the substrate was stirred and dissolved at room temperature, 500 mg (7.25 mmol) of sodium nitrite was added, stirred for 1 minute, and then slowly added dropwise the mixed solution prepared by 0.5 mL of 45% HI solution and 2 mL of acetonitrile solution. A reddish-brown gas was generated, and after stirring at room temperature for 2 hours, the same amount of HI acetonitrile solution was added to continue the reaction for 2-3 hours, and TCL monitoring indicated that the reaction ended (developing agent: 5% CH 3 OH / CH 2 Cl 2 ). Transfer the reaction solution to a 50mL beaker, and use K 2 CO 3 The solution (1g / 8mL) was adjusted to neutrality, and the color of the solution changed from black to yellow. CH 2 Cl 2 Extract the organic phase (3 × 20mL), combine the organic p...

Embodiment 3

[0056] Embodiment 3 Drug efficacy test of the compound of the present invention

[0057] Using the MTT assay, it is a yellow compound, a dye that accepts hydrogen ions, and can act on the respiratory chain in the mitochondria of living cells. Under the action of succinate dehydrogenase and cytochrome C, the tetrazolium ring is cracked to produce blue Formanzan crystals, the amount of formanzan crystals generated is only proportional to the number of viable cells, the formanzan crystals generated by reduction can be dissolved in dimethyl sulfoxide (DMSO), and the optical density (OD) value at 490nm is measured by a microplate reader. The number of living cells can be reflected.

[0058] 1. Experimental steps

[0059] Lung cancer cell lines: A549 and H1299.

[0060] Experimental supplies: lung cancer cell lines, tools required for cell culture, MTT and compound mother solution are 10mmol / L.

[0061] 1. Specific methods.

[0062] (3-1) A549 and H1299 cells were resuscitated, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a (1,2,4) triazol (1,5-a) pyridine derivative crystal form with the antitumor activity, and discloses a crystal form A of a compound shown in the formula (I) (please see the specification) and a crystal form B of a compound shown in the formula (II) (please see the specification). The compounds have the remarkable inhibiting effect on tumor cells, can be used for preventing and / or treating tumor related diseases, and particularly can be used for preventing and / or treating lung cancer. In this way, the crystal form has the broad application prospects.

Description

technical field [0001] The present invention relates to a crystal form of [1,2,4]triazolo[1,5-a]pyridine derivatives with antitumor activity. Background technique [0002] At present, lung cancer is one of the malignant tumors with the fastest increasing morbidity and mortality and the greatest threat to the health and life of the population. [0003] However, although there are many drugs for treating lung cancer on the market, they all have various defects, such as low bioavailability, low specificity, and large toxic and side effects. These defects are often caused by the structural characteristics of the compound itself and its target, which are difficult to overcome in further research and development. [0004] Therefore, those skilled in the art hope to synthesize a variety of compounds with different structures and their various crystal forms and to explore new targets to overcome the aforementioned defects. Contents of the invention [0005] To solve the above pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/04A61K31/5377A61P35/00
CPCC07B2200/13C07D471/04
Inventor 李为民何杨张立
Owner WEST CHINA HOSPITAL SICHUAN UNIV